Obagi Medical Products (NASDAQ: OMPI)‘s stock had its “neutral” rating restated by analysts at Piper Jaffray in a research report issued to clients and investors on Friday. They currently have a $13.00 price target on the stock, up from their previous price target of $12.00.
The analysts wrote, “Obagi reported 4Q12 adjusted diluted EPS of $0.15 (including $1.7M of spending related to the ongoing build-out of the company’s e-commerce platform), beating the Street estimate of $0.14. Revenues were in line with the Street, with Nu-Derm up 4% over 4Q11. The growth outlook however is murky in our view given that Allergan (via its SkinMedica unit) launched a non-hydroquinone-based skin lightening product in January 2013. Given the competitive dynamics surrounding Nu-Derm and the added expense and questionable benefits associated with the e-commerce platform in our view, we believe the outlook for sustainable longer-term earnings growth is uncertain.”
Separately, analysts at Cantor Fitzgerald upgraded shares of Obagi Medical Products from a “hold” rating to a “buy” rating in a research note to investors on Friday. They now have a $19.00 price target on the stock, up previously from $15.00.
One analyst has rated the stock with a buy rating, and three have issued a hold rating to the company. The stock currently has a consensus rating of “hold” and an average target price of $14.33.
Shares of Obagi Medical Products (NASDAQ: OMPI) traded up 7.96% during mid-day trading on Friday, hitting $15.05. Obagi Medical Products has a one year low of $10.70 and a one year high of $18.00. The stock’s 50-day moving average is currently $14.00. The company has a market cap of $262.1 million and a P/E ratio of 17.92.
Obagi Medical Products (NASDAQ: OMPI) last issued its quarterly earnings data on Thursday, March 14th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.06. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $30.06 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Obagi Medical Products has set its Q1 guidance at $0.09-0.10 EPS and its FY13 guidance at $0.80-0.84 EPS. On average, analysts predict that Obagi Medical Products will post $0.88 earnings per share for the current fiscal year.
Obagi Medical Products, Inc. is a specialty pharmaceutical company that develops, markets and sells, and is a provider of topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
